Boston Scientific (NYSE:BSX) announced positive data from a randomized clinical trial evaluating its EKOS endovascular system.

Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endova ...

LOS ANGELES, CA—The outcomes of mechanical thrombectomy in patients with acute ischemic stroke caused by large-vessel occlusions appear similar regardless of whether the procedure is preceded by IV ...

In high-risk STEMI patients who fail thrombolysis and subsequently undergo coronary revascularization with PCI, the transradial approach yields significant clinical advantages over the femoral route, ...

In patients presenting at thrombectomy-capable stroke centers, the benefit associated with thrombolysis plus thrombectomy vs thrombectomy alone was time dependent and statistically significant only if ...

Background: The role of immediate transfer for percutaneous coronary intervention (PCI) after thrombolysis for ST-segment elevation myocardial infarction remains controversial. We performed a ...

In this report, we showed that catheter-directed thrombolysis may bring benefit to patients with persistent symptoms after incomplete ST. Vigilance to such clinical situations and awareness of ...

Treating brain hemorrhage (symptomatic intracerebral hemorrhage, sICH) after clot-busting thrombolysis for stroke was not associated with a reduced likelihood of in-hospital death or expansion of the ...

Thrombolytic therapy continues to be an effective treatment for acute myocardial infarction when emergency coronary angioplasty is not available. 1,2 We describe a spontaneous retro-orbital hemorrhage ...

The proof of efficacy of thrombolysis for acute myocardial infarction (AMI) depends on 9 randomized placebo-controlled trials totaling 58,511 patients. The meta-analysis of these trials showed an ...

Controversy exists over whether chronic antiplatelet therapy in patients with acute ischemic stroke is a contraindication to treatment with tissue plasminogen activator (tPA). Antiplatelets impair ...